RELIEF Therapeutics Holding AG Logo

RELIEF Therapeutics Holding AG

Developing and commercializing novel therapies for rare and ultra-rare diseases.

RLF | SW

Overview

Corporate Details

ISIN(s):
CH1251125998
LEI:
506700IT19260EVD7916
Country:
Switzerland
Address:
avenue de Sécheron 15, 1202 Genève
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

RELIEF Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for rare and ultra-rare diseases with high unmet medical needs. The company's mission is to advance its pipeline of therapeutic candidates to provide patients with treatments that can significantly improve their condition and quality of life. Its strategy involves advancing clinical programs, such as its candidate for Epidermolysis Bullosa (RLF-TD011), and pursuing strategic transactions, including partnerships and business combinations, to accelerate development and market access for its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 07:00
M&A Activity
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
English 19.8 KB
2025-10-08 02:00
M&A Activity
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
English 17.3 KB
2025-08-14 07:00
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
English 9.0 KB
2025-08-14 02:00
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
English 6.8 KB
2025-08-11 07:00
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
English 6.9 KB
2025-08-11 02:00
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
English 4.8 KB
2025-07-29 07:00
M&A Activity
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
English 15.9 KB
2025-07-29 02:00
M&A Activity
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
English 13.6 KB
2025-06-20 07:00
Legal Proceedings Report
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
English 10.7 KB
2025-06-20 02:00
Regulatory News Service
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
English 8.5 KB
2025-06-12 11:00
Post-Annual General Meeting Information
Relief Therapeutics Announces Results of Annual General Meeting
English 10.5 KB
2025-06-12 02:00
Post-Annual General Meeting Information
Relief Therapeutics Announces Results of Annual General Meeting
English 8.3 KB
2025-05-22 07:00
Regulatory News Service
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD0…
English 11.7 KB
2025-05-22 02:00
Regulatory News Service
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD0…
English 9.5 KB
2025-05-15 07:00
Pre-Annual General Meeting Information
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
English 8.6 KB

Automate Your Workflow. Get a real-time feed of all RELIEF Therapeutics Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RELIEF Therapeutics Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP

Talk to a Data Expert

Have a question? We'll get back to you promptly.